Abstract Book

S820

ESTRO 37

Material and Methods Retrospective, descriptive study of premenopausal cervix cancer who received radiotherapy at pelvic region at Mahavajiralongkorn Thanyaburi Hospital between 1 October 2007 and 30 September 2012. Results The total 163 patients, median age were 43.23 + 4.68 (28.4 - 52.1) years old and median BMI was 24.65 + 4.49 (15.79 – 41.65) kg/m 2 . The most common was uterine cervical cancer stage IIB (52.76%) and received radiotherapy with four fields box technique (57.67%), intracavitary high dose rate brachytherapy (98.77%) and without chemotherapy treatment (61.97%). There were no smoking (93.87%), no alcohol drinking (88.67%), no coffee or tea drinking (80.98%), no exercise (75.46%) and no previous bone fracture (95.09%). More than ninety percent of patients were no previous hysterectomy and oophorectomy. All of most was not eating vitamin D and 73.01% was eating calcium usually. There was developed osteopenia and osteoporosis 22.70% and 6.13%, respectively. The factor which affected of osteopenia and osteoporosis in this study were history of coffee or tea drinking (p = 0.028), exercise (p = 0.010) and history of bone fracture (p = 0.034). Conclusion Radiotherapy at pelvic region in premenopausal cervix cancer was induced osteopenia and/or osteoporosis more than normal female population. The timing for developed osteopenia and/or osteoporosis as same as in female who underwent bilateral oophorectomy. M. Nuzzo 1 , G. Macchia 2 , T. Conte 2 , S. Cilla 3 , M. Boccardi 2 , M. Ferioli 4 , A. Galuppi 4 , R. Frakulli 4 , M. Buwenge 4 , G. Siepe 4 , S. Ciabatti 4 , L. Ronchi 4 , A. Cortesi 4,5 , E. Alexopoulou 6 , M. Perrone 7 , P.A. De Iaco 7 , S. Cammelli 4 , A.G. Morganti 4 , F. Deodato 2 1 Radiotherapy Unit, ‘SS Annunziata’ Hospital ‘G. D’Annunzio’ University, Chieti, Italy 2 Radiotherapy Unit, Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy 3 Medical Physics Unit, Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy 4 Radiation Oncology Center, Department of Experimental Diagnostic and Specialty Medicine - DIMES- University of Bologna, Bologna, Italy 5 Radiotherapy Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, IRCCS, Italy 6 Department of Radiation Oncology, University of Patras Medical School, Patras, Greece 7 Oncologic Gynecology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy Purpose or Objective Purpose/Objective. Vulvar carcinoma (VC) is a relatively rare type of malignancy and constitutes 3% of gynecological cancers. Due to rarity, age of onset and anatomic site, vulvar cancer is disregarded or underestimated up to a locally advanced stage. Chemoradiation treatments (CRT) before or after a more conservative surgery represents a promising option to reduce the volume of the tumor, allowing the radical resection and reducing the genital mutilation. Therefore, a systematic review of the literature in order to evaluate the efficacy and safety of chemoradiation treatments was performed, aimed to understand what is the best EP-1513 Systematic review about the role of chemoradiotherapy in locally advanced vulvar carcinoma

treatment regimen according to clinical setting in locally advanced VC. Material and Methods Material/Methods. From Pubmed (2000-2016) database, a literature search was performed including published prospective and retrospective English-language articles on CRT in locally advanced VC with more than 25 patients treated. The following data were recorded: number of patients, enrolment period, median follow up, treatment characteristics, chemotherapy regimen, and results in terms of toxicity and outcome. Results Results. Based on inclusion criteria, 7 studies were selected accounting for 291 patients (median number of patients per study: 42 (range: 28-58)). All but one studies were retrospective, with only one phase II trial. Studies were heterogeneous in terms of RT (dose, fractionation, techniques, use of brachytherapy [BRT] boost) and schedules of chemotherapy. 2D and 3D conformal RT were the most used techniques, while IMRT was used in two trials alone as well as BRT boost if surgery was not performed. Various concurrent chemotherapy schedules were administered: weekly Cisplatin (3/7), 5-Fluorouracil (1/7), 5-Fluorouracil + Cisplatin (3/7) or 5-Fluorouracil + Mytomicin C (2/7). Acute grade ≥ 3 toxicities were mostly cutaneous (range:14%-54%) and intestinal (range: 0%- 29.3%) ones, with a less frequency of bladder severe toxicity (range: 0%-7%). Data about the complete clinical response rate were reported in 5/7 studies (range: 28%- 72%), while the length of follow-up was very variable. An overview of clinical outcomes among studies is reported in the Table. Conclusion Conclusion. Only few mostly retrospective studies have been published in the last decade on CRT in locally advanced VC, probably due to the rarity of this tumor. Because of the long time span, there was a large heterogeneity in terms of treatment characteristics and evaluation criteria. Clinical results were strongly influenced by technical features. Prospective randomized studies are needed to better evaluate patients outcome, especially with modern high-precision RT techniques. EP-1514 Initial experience in inoperable endometrial cancer treated with EBRT plus HDR-BT. M.F. Ropero Carmona 1 , J. Quirós Rivero 1 , M.A. Gonzalez Ruiz 1 , C. Cruz Muñoz 1 , P. Simón Silva 1 , J.L. Muñoz Garcia 1 , J.J. Cabrera Rodriguez 1 , Y. Rios Kavadoy 1 , A. Corbacho Campos 1 1 Hospital Universitario Infanta Cristina, Radiotherapy Oncologist, Badajoz, Spain Purpose or Objective To report our experience in patients with inoperable endometrial cancer treated with EBRT + HDR-BT. Material and Methods From October 2015 to March 2017 seven patients with inoperable endometrial cancer stages I-III, underwent definitive treatment.